MDS Pharma Services and InnaPhase collaborate to enhance early drug development
The Watson LIMS will be implemented in five MDS bioanalytical research facilities, two in Montreal, Canada; one in Zurich, Switzerland; and two in the United States. The system is designed to support Bioanalytical/DMPK (Drug Metabolism/Pharmacokinetic) studies in drug development and maintains regulatory compliance with the FDA's 21 CRF Part 11 guidance on electronic records and signatures. The Watson system was developed in conjunction with pharmaceutical companies to accelerate bioanalysis and sample management in drug development.
"As a leading contract research organization, our clients expect rapid data turnaround and outstanding quality," said Jim Hulse, Senior Vice President of Bioanalytical Services at MDS Pharma Services. "The Watson LIMS allows us to standardize our reporting processes and manage our bioanalytical projects effectively to maintain our high level of customer service. With Watson, we will be able to coordinate more than 400 users and more than 100 advanced analytical instruments in our bioanalytical laboratories throughout the world."
"The Watson LIMS provides an integrated environment that standardizes laboratory processes and automatically generates data in an accurate, consistent manner," said Gary Rathsmill, Senior Vice President of Product Research at InnaPhase. "Knowledge management at this level results in significant time and cost savings allowing companies like MDS to become more competitive."